496807-11-5
中文名稱
sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
英文名稱
sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
CAS
496807-11-5
分子式
C24H29NaO5
分子量
420.474
MOL 文件
496807-11-5.mol
496807-11-5 結(jié)構(gòu)式
基本信息
中文別名
(RAC)-貝拉前列素鈉貝拉前列素鈉鹽(非對映異構(gòu)體混合物)
英文別名
Beraprost sodium (Relative stereochemistry)sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
常見問題列表
生物活性
Beraprost sodium 是一種前列環(huán)素類似物，是一種穩(wěn)定且具有口服活性的 PGI2 前藥。Beraprost sodium 是有效的血管擴張劑 (vasodilator)，通過擴張腎血管，改善微循環(huán)而具有研究肺動脈高壓的潛力。靶點
prodrug of PGI2; Vasodilator
體外研究
Beraprost sodium (0.1, 1.0, and 10.0?μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity. Beraprost sodium (0.1, 1.0, and 10.0?μM; 24 hours) treatment let VE-cadherin at regions of cell–cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions.
體內(nèi)研究
Beraprost sodium (oral adminstration; 0.6?mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis.
| Animal Model: | 6-8-week-old C57Bl/6J Male Mice |
| Dosage: | 0.6?mg/kg |
| Administration: | Oral adminstration; 0.6?mg/kg; once daily; 3 or 7 days |
| Result: | Mitigated the development of renal interstitial fibrosis. |